全身麻酔薬の市場規模、シェア、成長分析、薬剤タイプ別、投与経路別、最終用途別、地域別 - 産業予測、2025～2032年

全身麻酔薬市場規模は2023年に55億9,000万米ドルと評価され、2024年の57億9,000万米ドルから2032年には79億7,000万米ドルに成長し、予測期間（2025-2032年）のCAGRは3.5％で成長する見通しです。

全身麻酔市場は、主に手術件数の増加と新しい麻酔薬のイントロダクションよって、大きな成長を遂げています。世界では毎年3億1,000万件の大手術が実施されており、美容整形や再建手術の増加が顕著であることから、静脈内（IV）麻酔薬の需要は、特に心血管疾患や慢性腎疾患を抱える患者に対して高まっています。PainPassのCBD/リドカインラインやHikma Pharmaceuticalsのブピバカイン塩酸塩注射液のような革新的な局所麻酔薬は、市場拡大にさらに貢献しています。さらに、PAION AGのByfavoのような手技用鎮静剤の規制状況は、進化する状況を示しています。これらの動向は、手術件数と製品革新の両方が増加し続ける全身麻酔の堅調な市場推移を示しています。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次データと一次データの方法
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の見通し
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と見通し

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターの分析

主な市場の考察

• 重要成功要因
• 競合の程度
• 主な投資機会
• 市場エコシステム
• 市場の魅力指数（2024年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析
• 規制情勢
• 特許分析

全身麻酔薬市場規模：薬剤タイプ別

• 市場概要
• プロポフォール
• セボフルラン
• デスフルラン
• ケタミン
• チオペンタール
• エトミデート
• その他

全身麻酔薬市場規模：投与経路別

• 市場概要
• 静脈内
  • ボーラス注射
  • 持続注入
• 吸入
  • 揮発性液体
  • ガス

全身麻酔薬市場規模：最終用途別

• 市場概要
• 病院
• 外来手術センター
• クリニック
• その他

全身麻酔薬市場規模：用途別

• 市場概要
• 心臓血管外科
• 整形外科
• 脳神経外科
• 一般外科
• 美容整形
• その他

全身麻酔薬市場規模

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2024年）
• 主な市場企業が採用した戦略
• 市場の最近の動向
• 企業の市場シェア分析（2024年）
• 主要企業の企業プロファイル
  • 会社概要
  • 製品ポートフォリオ分析
  • セグメント別シェア分析
  • 収益の前年比比較（2022-2024）

主要企業プロファイル

• AstraZeneca（UK）
• Baxter International Inc.（USA）
• Fresenius SE & Co. KGaA（Germany）
• AbbVie Inc.（USA）
• B. Braun Melsungen AG（Germany）
• Hikma Pharmaceuticals PLC（UK）
• Teva Pharmaceutical Industries Ltd.（Israel）
• Pfizer Inc.（USA）
• Novartis AG（Switzerland）
• Mylan N.V.（USA）
• Piramal Enterprises Limited（India）
• Eisai Co., Ltd.（Japan）
• F. Hoffmann-La Roche Ltd.（Switzerland）
• GlaxoSmithKline plc（UK）
• Johnson & Johnson（USA）
• Merck & Co., Inc.（USA）
• Sanofi S.A.（France）
• Sun Pharmaceutical Industries Ltd.（India）
• Takeda Pharmaceutical Company Limited（Japan）
• Abbott Laboratories（USA）

結論と推奨事項

General Anesthesia Drugs Market size was valued at USD 5.59 Billion in 2023 and is poised to grow from USD 5.79 Billion in 2024 to USD 7.97 Billion by 2032, growing at a CAGR of 3.5% during the forecast period (2025-2032).

The general anaesthesia market is witnessing significant growth, primarily driven by the rising number of surgical procedures and the introduction of new anaesthetic medications. With 310 million major surgeries conducted globally each year and a notable increase in cosmetic and reconstructive procedures, the demand for intravenous (IV) anaesthetics is escalating, particularly for patients with cardiovascular and chronic renal diseases. Innovative local anaesthetic products, such as PainPass's CBD/lidocaine line and Hikma Pharmaceuticals' Bupivacaine HCl Injection, further contribute to market expansion. Additionally, regulatory approvals like PAION AG's Byfavo for procedural sedation demonstrate an evolving landscape. These trends indicate a robust market trajectory for general anaesthesia as both surgical volumes and product innovations continue to rise.

Top-down and bottom-up approaches were used to estimate and validate the size of the General Anesthesia Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

General Anesthesia Drugs Market Segmental Analysis

Global General Anesthesia Drugs Market is segmented by drug type, Route of Administration, end-use, application and region. Based on drug type, the market is segmented into propofol, sevoflurane, desflurane, ketamine, thiopental, etomidate and others. Based on route of administration, the market is segmented into intravenous and inhaled. Based on end-use, the market is segmented into hospitals, ambulatory surgical centers, clinics and others. Based on application, the market is segmented into cardiovascular surgery, orthopedic surgery, neurosurgery, general surgery, cosmetic surgery and others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the General Anesthesia Drugs Market

The growth of the general anesthesia drugs market is significantly driven by the rising incidence of cancer in the United States. Recent estimates from the National Cancer Institute indicate that there are currently around 16.9 million cancer survivors, with projections suggesting this figure could reach 22.2 million by 2030. The prevalence of various cancers, including lung, breast, and prostate cancer, is increasing, which leads to a greater need for surgical interventions. As surgeries, particularly for malignant tumors, present the most effective treatment option when cancer is localized, the demand for general anesthesia is expected to rise correspondingly, propelling the market forward.

Restraints in the General Anesthesia Drugs Market

The General Anesthesia Drugs market faces significant restraint due to the associated risks in pediatric patients and pregnant women. Caution is paramount when administering general anesthetics to infants and young children, as their physiological responses differ from adults, influenced by aspects like body composition and the maturation of organ functions. Research has highlighted potential dangers, such as extensive nerve cell death in young animals following prolonged exposure to these drugs, leading to increased scrutiny within human studies. The FDA has further issued warnings about the risks of prolonged or repeated use in children under three and pregnant women, leading healthcare providers to reconsider the adoption of these anesthetic treatments, which may hinder market growth.

Market Trends of the General Anesthesia Drugs Market

The General Anesthesia Drugs market is witnessing significant growth, driven by intensive research and development efforts aimed at enhancing clinical outcomes and patient recovery. Notable studies, such as those from the University of Michigan and Washington University School of Medicine, are assessing the efficacy of existing anesthetics, including inhaled agents and intravenous propofol, to refine usage protocols. This focus on evidence-based practice is poised to improve patient care, making anesthetics safer and more effective. As a result, the market is likely to expand, fueled by innovations that meet the increasing demands of surgical procedures and patient safety standards throughout the forecast period.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Landscape
• Patent Analysis

Global General Anesthesia Drugs Market Size by Drug Type & CAGR (2025-2032)

• Market Overview
• Propofol
• Sevoflurane
• Desflurane
• Ketamine
• Thiopental
• Etomidate
• Others

Global General Anesthesia Drugs Market Size by Route of Administration & CAGR (2025-2032)

• Market Overview
• Intravenous
  • Bolus Injection
  • Continuous Infusion
• Inhaled
  • Volatile Liquids
  • Gases

Global General Anesthesia Drugs Market Size by End-Use & CAGR (2025-2032)

• Market Overview
• Hospitals
• Ambulatory Surgical Centers
• Clinics
• Others

Global General Anesthesia Drugs Market Size by Application & CAGR (2025-2032)

• Market Overview
• Cardiovascular Surgery
• Orthopedic Surgery
• Neurosurgery
• General Surgery
• Cosmetic Surgery
• Others

Global General Anesthesia Drugs Market Size & CAGR (2025-2032)

• North America (Drug Type, Route of Administration, End-Use, Application)
  • US
  • Canada
• Europe (Drug Type, Route of Administration, End-Use, Application)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Drug Type, Route of Administration, End-Use, Application)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Drug Type, Route of Administration, End-Use, Application)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Drug Type, Route of Administration, End-Use, Application)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• AstraZeneca (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Baxter International Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fresenius SE & Co. KGaA (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• B. Braun Melsungen AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hikma Pharmaceuticals PLC (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mylan N.V. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Piramal Enterprises Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eisai Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd. (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations